Annals of Oncology最新文献

{"title":"Time to rethink platinum choices in the era of immunotherapy in lung cancer","authors":"E. Harris , N.F. Taflin , A. Chitkara , M. Tagliamento , C.M. Bestvina , C.V. Vakkalagadda , B. Besse , R. Thawani","doi":"10.1016/j.annonc.2024.10.009","DOIUrl":"10.1016/j.annonc.2024.10.009","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 2","pages":"Pages 218-220"},"PeriodicalIF":56.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the Letter to the Editor “Odronextamab against relapsed or refractory follicular lymphoma” by Y. Shimazu","authors":"T.M. Kim , A. Chaudhry , H. Mohamed , B. Shen , S. Ambati","doi":"10.1016/j.annonc.2024.10.016","DOIUrl":"10.1016/j.annonc.2024.10.016","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 2","pages":"Pages 222-223"},"PeriodicalIF":56.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating tumor DNA after definitive therapy for locally advanced rectal cancer","authors":"S. Sorscher , C.M.S.P. Rocha-Lima","doi":"10.1016/j.annonc.2024.10.825","DOIUrl":"10.1016/j.annonc.2024.10.825","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 2","pages":"Pages 223-224"},"PeriodicalIF":56.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?","authors":"T. Nishimura , H. Fujimoto","doi":"10.1016/j.annonc.2024.10.010","DOIUrl":"10.1016/j.annonc.2024.10.010","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 2","pages":"Pages 220-221"},"PeriodicalIF":56.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial","authors":"P. Harter ,&nbsp;C. Marth ,&nbsp;M.-A. Mouret-Reynier ,&nbsp;C. Cropet ,&nbsp;D. Lorusso ,&nbsp;E.M. Guerra-Alía ,&nbsp;T. Matsumoto ,&nbsp;I. Vergote ,&nbsp;N. Colombo ,&nbsp;J. Mäenpää ,&nbsp;C. Lebreton ,&nbsp;N. de Gregorio ,&nbsp;A.M. Mosconi ,&nbsp;M.J. Rubio-Pérez ,&nbsp;H. Bourgeois ,&nbsp;P.A. Fasching ,&nbsp;S.C. Cecere ,&nbsp;A.-C. Hardy-Bessard ,&nbsp;D. Denschlag ,&nbsp;S. de Percin ,&nbsp;María Jesús Rubio-Pérez","doi":"10.1016/j.annonc.2024.10.828","DOIUrl":"10.1016/j.annonc.2024.10.828","url":null,"abstract":"<div><h3>Background</h3><div>The use of first-line poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is increasing in advanced ovarian cancer. Understanding the efficacy of first subsequent therapy (FST) in patients experiencing disease progression in the first-line setting is important to optimize postprogression treatments. We evaluated the efficacy of FST in patients from PAOLA-1/ENGOT-ov25 (NCT02477644) who received first-line olaparib maintenance.</div></div><div><h3>Patients and methods</h3><div>This <em>post hoc</em> analysis evaluated the efficacy of subsequent chemotherapy following disease progression by assessing time from FST to second subsequent therapy (SST) according to whether progression occurred during versus after first-line olaparib maintenance and FST type. A multivariate Cox model was used in the olaparib plus bevacizumab arm to identify prognostic factors influencing the efficacy of subsequent chemotherapy.</div></div><div><h3>Results</h3><div>Of 806 randomized patients, 544 (67.5%) progressed and received subsequent chemotherapy. The median time from FST to SST was shorter in patients in the olaparib plus bevacizumab arm who progressed during first-line olaparib maintenance (6.1 months) than in those who progressed after first-line olaparib maintenance (11.4 months). Multivariate analysis indicated that progression after (versus during) first-line olaparib maintenance influenced time from FST to SST (hazard ratio 0.65, 95% confidence interval 0.50-0.84; <em>P</em> = 0.0011) independently of platinum-free interval or clinical risk. Among patients who progressed and received platinum-based chemotherapy with a PARP inhibitor as FST, the efficacy of subsequent therapies was also dependent on whether progression occurred during versus after first-line olaparib maintenance.</div></div><div><h3>Conclusions</h3><div>These results suggest that the timing of disease progression relative to first-line olaparib maintenance may impact the efficacy of subsequent platinum-based chemotherapy. Although results should be interpreted with caution, across all subgroups, including patients who received platinum-based chemotherapy with PARP inhibitor rechallenge as FST, the median time from FST to SST was longer if progression occurred after versus during first-line olaparib maintenance.</div></div>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 2","pages":"Pages 185-196"},"PeriodicalIF":56.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial","authors":"D. Baron ,&nbsp;T. Pace Loscos ,&nbsp;R. Schiappa ,&nbsp;N. Barbet ,&nbsp;E. Dost ,&nbsp;S. Ben Dhia ,&nbsp;S. Soltani ,&nbsp;L. Mineur ,&nbsp;I. Martel ,&nbsp;S. Horn ,&nbsp;C. Picardi ,&nbsp;A. Stewart ,&nbsp;E. Cotte ,&nbsp;R. Coquard ,&nbsp;G. Baudin ,&nbsp;L. Evesque ,&nbsp;A. Dhadda ,&nbsp;A. Sun Myint ,&nbsp;J.P. Gérard ,&nbsp;J. Doyen","doi":"10.1016/j.annonc.2024.10.827","DOIUrl":"10.1016/j.annonc.2024.10.827","url":null,"abstract":"<div><h3>Background</h3><div>The OPERA trial has shown that a contact X-ray brachytherapy 50 kV (CXB) boost with neoadjuvant chemoradiotherapy (NCRT) can increase organ preservation (OP) rate for early rectal adenocarcinoma (ADK) of low-mid rectum. We report the results after 5 years of follow-up.</div></div><div><h3>Patients and methods</h3><div>OPERA was a multicentre, phase III trial that included operable patients (pts), with cT2-cT3b low-mid rectal ADK, tumours &lt;5 cm, cN0 or cN1 &lt;8 mm. All pts received external beam radiotherapy (EBRT): 45 Gy in 25 fractions with concurrent capecitabine. Pts were randomly assigned (1:1) to receive a boost of EBRT in group A (9 Gy/5 fractions) or a boost with CXB (90 Gy/3 fractions) in group B. The primary end point was OP rate.</div></div><div><h3>Results</h3><div>Out of 148 patients randomised, 141 were eligible. Between week 14-24, a clinical complete (or near) response was observed in 44 pts in group A (64%) versus 66 in group B (92%); <em>P</em> &lt; 0.001. The 3-year OP rate was 59% in group A versus 81% in group B (<em>P</em> = 0.003). After update the median follow-up was 61.1 months [56.8-64.5]. The 5-year local regrowth was 39% in group A and 17% in group B (<em>P</em> = 0.1). The difference in OP was still highly significant between both groups: A 56% versus B 79% (<em>P</em> = 0.004). The difference was more significant if tumours &lt;3 cm, with an OP rate of 93% in group B compared to 54% in group A. Of the 28 local regrowths, 3 occurred after 3 years of follow-up. Rectal bleeding (grade 1-2), which was the most prevalent toxicity during follow-up, disappeared most of the time after three years. Bowel function was not worsened by the CXB boost.</div></div><div><h3>Conclusion</h3><div>The OPERA trial was the first trial to demonstrate that CXB dose escalation was increasing the OP rate with good bowel function at 3 years. At 5 years, these results are sustained, especially in small early-stage tumours. The occurrence of some local regrowth after 3 years necessitates close surveillance of these pts during the 5-year period.</div></div>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 2","pages":"Pages 208-215"},"PeriodicalIF":56.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the Letter to the Editor ‘Circulating tumor DNA after definitive therapy for locally advanced rectal cancer’ by Drs Sorscher and Rocha Lima","authors":"A. Bercz ,&nbsp;J.J. Smith ,&nbsp;P.B. Romesser","doi":"10.1016/j.annonc.2024.10.826","DOIUrl":"10.1016/j.annonc.2024.10.826","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 2","pages":"Pages 224-225"},"PeriodicalIF":56.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the Letter to the Editor regarding ‘Chi-squared and P-values vs. machine learning feature selection by Y. Takefuji’","authors":"N. Fraunhoffer ,&nbsp;J. Iovanna ,&nbsp;N. Dusetti","doi":"10.1016/j.annonc.2024.10.014","DOIUrl":"10.1016/j.annonc.2024.10.014","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 2","pages":"Pages 228-229"},"PeriodicalIF":56.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142602785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the Letter to the Editor regarding ‘PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?’ by T. Nishimura and H. Fujimoto","authors":"E. Felip ,&nbsp;B.C. Cho ,&nbsp;D. Nguyen ,&nbsp;J.C. Curtin ,&nbsp;S. Sethi ,&nbsp;J.M. Bauml ,&nbsp;S.-H. Lee","doi":"10.1016/j.annonc.2024.10.011","DOIUrl":"10.1016/j.annonc.2024.10.011","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 2","pages":"Pages 221-222"},"PeriodicalIF":56.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial","authors":"L.A. Huppert ,&nbsp;D. Wolf ,&nbsp;C. Yau ,&nbsp;L. Brown-Swigart ,&nbsp;G.L. Hirst ,&nbsp;C. Isaacs ,&nbsp;L. Pusztai ,&nbsp;P.R. Pohlmann ,&nbsp;A. DeMichele ,&nbsp;R. Shatsky ,&nbsp;D. Yee ,&nbsp;A. Thomas ,&nbsp;R. Nanda ,&nbsp;J. Perlmutter ,&nbsp;D. Heditsian ,&nbsp;N. Hylton ,&nbsp;F. Symmans ,&nbsp;L.J. van’t Veer ,&nbsp;L. Esserman ,&nbsp;H.S. Rugo","doi":"10.1016/j.annonc.2024.10.018","DOIUrl":"10.1016/j.annonc.2024.10.018","url":null,"abstract":"<div><h3>Background</h3><div>Hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer (EBC) is a heterogenous disease. Identification of better clinical and molecular biomarkers is essential to guide optimal therapy for each patient.</div></div><div><h3>Patients and methods</h3><div>We analyzed rates of pathologic complete response (pCR) and distant recurrence-free survival (DRFS) for patients with HR+/HER2-negative EBC in eight neoadjuvant arms in the I-SPY2 trial by clinical/molecular features: age, stage, histology, percentage estrogen receptor (ER) positivity, ER/progesterone receptor status, MammaPrint (MP)-High1 (0 to −0.57) versus MP-High2 (&lt;−0.57), BluePrint (BP)-Luminal-type versus BP-Basal-type, and ImPrint immune signature. We quantified the clinical/molecular heterogeneity, assessed overlap among these biomarkers, and evaluated associations with pCR and DRFS.</div></div><div><h3>Results</h3><div>Three hundred and seventy-nine patients with HR+/HER2-negative EBC were included in this analysis, with an observed pCR rate of 17% across treatment arms. pCR rates were higher in patients with stage II versus III disease (21% versus 9%, <em>P</em> = 0.0013), ductal versus lobular histology (19% versus 11%, <em>P</em> = 0.049), lower %ER positivity (≤66% versus &gt;66%) (35% versus 9%, <em>P</em> = 3.4E-09), MP-High2 versus MP-High1 disease (31% versus 11%, <em>P</em> = 1.1E-05), BP-Basal-type versus BP-Luminal-type disease (34% versus 10%, <em>P</em> = 1.62E-07), and ImPrint-positive versus -negative disease (38% versus 10%, <em>P</em> = 1.64E-09). Patients with lower %ER were more likely to have MP-High2 and BP-Basal-type disease. At a median follow-up of 4.8 years, patients who achieved pCR had excellent outcomes irrespective of clinical/molecular features. Among patients who did not achieve pCR, DRFS events were more frequent in patients with MP-High2 and BP-Basal-type disease than those with MP-High1 and BP-Luminal-type disease.</div></div><div><h3>Conclusions</h3><div>Among patients with high molecular-risk HR+/HER2-negative EBC, the MP-High2, BP-Basal-type, and ImPrint-positive signatures identified a partially overlapping subset of patients who were more likely to achieve pCR in response to neoadjuvant chemotherapy ± targeted agents or immunotherapy compared to patients with MP-High1, BP-Luminal-type, and ImPrint-negative disease. I-SPY2.2 is incorporating the use of these biomarkers to molecularly define specific patient populations and optimize treatment selection.</div></div>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 2","pages":"Pages 172-184"},"PeriodicalIF":56.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}